# Tirzepatide Research: Mechanism, SURMOUNT and SURPASS Trial Evidence > Tirzepatide research: the dual GIP/GLP-1 mechanism of action, the SURMOUNT weight-loss trials, SURPASS glycaemic data, and recent findings from 2024–2025. Cited from the peer-reviewed literature. ## The short version Tirzepatide research spans a molecular discovery paper, a pharmacology characterisation study, five phase 3 diabetes trials, five obesity trials, and dedicated investigations into sleep apnea, heart failure, and metabolic liver disease. This page summarises the evidence in order of depth: first the mechanism, then the key trial results, then the 2024–2025 updates. Every quantitative figure is cited. Tirzepatide is the first FDA-approved dual incretin agonist, meaning it activates two different gut-hormone receptors — GIP and GLP-1 — with a single molecule, producing glycaemic and weight effects that trials have shown to exceed those of GLP-1 agonism alone. ## Tirzepatide mechanism of action Tirzepatide is a 39-amino-acid synthetic peptide that activates both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). These two incretin hormones (gut-derived hormones that amplify insulin release in response to food) share overlapping but distinct physiological effects: GIP primarily enhances insulin secretion from the pancreas and influences fat storage; GLP-1 additionally suppresses glucagon (a hormone that raises blood glucose), delays gastric emptying (slowing the rate at which food leaves the stomach), and reduces appetite through central nervous system pathways. In vitro receptor characterisation found tirzepatide engages the GIP receptor to a greater extent than the GLP-1 receptor — a profile described as 'imbalanced' dual agonism — and shows biased GLP-1 receptor signalling that preferentially activates the cAMP intracellular signalling pathway over beta-arrestin recruitment. Because beta-arrestin1 limits the insulin response to GLP-1 but not to GIP, this biased engagement may enhance the net insulin-secretory effect [2]. The practical clinical relevance of this receptor pharmacology profile has not been fully characterised. The fatty diacid arm attached to the peptide backbone binds serum albumin, extending the half-life to approximately five days and enabling once-weekly subcutaneous dosing [1, 7]. The proof-of-concept phase 1 programme in 142 subjects (healthy volunteers and people with type 2 diabetes) confirmed pharmacokinetics consistent with once-weekly dosing and demonstrated reductions in fasting glucose and body weight versus placebo [1]. ## Key trial findings: the SURMOUNT programme SURMOUNT-1 (n=2,539, 72 weeks, double-blind RCT) enrolled adults with obesity (BMI ≥30, or ≥27 with a weight-related complication) without diabetes. Once-weekly subcutaneous tirzepatide produced mean body-weight changes of -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg) versus -3.1% with placebo. The most common adverse events were gastrointestinal and mostly mild to moderate, occurring primarily during dose escalation [4]. SURMOUNT-2 (10 mg and 15 mg, 72 weeks) enrolled adults with both obesity and type 2 diabetes and demonstrated substantial body-weight reductions versus placebo in that co-morbid population [9]. SURMOUNT-3 (n=579, 72 weeks from randomisation) added tirzepatide after a 12-week intensive lifestyle intervention. Participants achieving ≥5% weight reduction from lifestyle alone were then randomised. The mean additional weight change was -18.4% with tirzepatide versus +2.5% with placebo; 87.5% of tirzepatide participants achieved ≥5% additional weight reduction versus 16.5% with placebo [10]. SURMOUNT-4 (randomised withdrawal design) demonstrated that participants switched to placebo regained weight substantially while those continuing tirzepatide maintained loss, establishing that the effect depends on continued treatment [13]. SURMOUNT-5 (n=751, 72 weeks, open-label head-to-head) enrolled adults with obesity without type 2 diabetes. Maximum-tolerated tirzepatide produced -20.2% body weight versus -13.7% with maximum-tolerated semaglutide (another approved GLP-1 medicine) (P<0.001). Higher proportions reached ≥10%, ≥15%, ≥20%, and ≥25% weight loss with tirzepatide [5]. The SURMOUNT-OSA trial documented significant reduction in apnea-hypopnea index (AHI, the number of breathing interruptions per hour of sleep) alongside weight reduction in adults with obesity and moderate-to-severe obstructive sleep apnea [12]. ## Tirzepatide vs semaglutide: the head-to-head evidence Two pivotal comparisons document the relative performance of tirzepatide against the approved GLP-1 medicine semaglutide. SURPASS-2 (n=1,879, 40 weeks, open-label) compared tirzepatide 5, 10, and 15 mg against semaglutide 1 mg in adults with type 2 diabetes. Tirzepatide reduced HbA1c by 2.01, 2.24, and 2.30 percentage points versus 1.86 with semaglutide; tirzepatide was noninferior and superior at all three doses. Weight reductions were -1.9, -3.6, and -5.5 kg greater with tirzepatide than semaglutide [3]. SURMOUNT-5 (n=751, 72 weeks) compared maximum-tolerated tirzepatide against maximum-tolerated semaglutide for obesity without type 2 diabetes. Tirzepatide -20.2% versus semaglutide -13.7% in body weight (P<0.001) [5]. This represents the largest direct comparison of these two agents in a randomised trial. The comparison channel: the two-receptor mechanism produces larger effects than single GLP-1 receptor agonism in head-to-head trials. The tolerability trade-off — higher discontinuation rates due to GI events versus a comparable incretin — is documented in a meta-analysis of three head-to-head trials versus another approved agent [33]. ## 2024–2025 updates and extended programme Three recent studies extend the evidence base. Tirzepatide for Obesity Treatment and Diabetes Prevention (NEJM, 2025) assessed sustained weight reduction and reduced progression to type 2 diabetes over a longer follow-up period [36]. Gastrointestinal adverse events and weight reduction (Diabetes, Obesity & Metabolism, 2024) established that the weight reduction seen in the SURPASS trials is not attributable solely to gastrointestinal adverse events — the reduction occurs even in participants who did not experience significant GI effects [37]. Population pharmacokinetics (CPT Pharmacometrics, 2024) confirmed the population PK profile supporting once-weekly subcutaneous dosing across the trial population [7]. The dedicated SUMMIT trial (NEJM, 2025) reported tirzepatide outcomes in heart failure with preserved ejection fraction (HFpEF — a form of heart failure in which the heart's pumping fraction remains normal) in adults with obesity, extending the evidence beyond weight and glycaemia [11]. The SYNERGY-NASH trial (NEJM, 2024) evaluated tirzepatide in MASH (metabolic dysfunction-associated steatohepatitis, a progressive fatty liver disease), demonstrating liver histology benefits [35]. SURMOUNT-OSA (NEJM, 2024) documented AHI reduction in obstructive sleep apnea [12]. --- A documented reading of the tirzepatide trial record — SURMOUNT, SURPASS, and the extended programme — cited to source, with evidence gaps and safety signals kept in plain view; no clinic behind the name, no prescription written, and nothing here dosed or sold.